Excerpts

Although overall hospital readmissions have been declining, our analysis revealed an increasing trend in the Elixhauser Comorbidity Index, which rose gradually from 3.8 to 4.0 over four years.

Second, among participants with complete three-timepoint data at baseline, six months, and 12 months (n = 14), SF-BBS scores showed a positive trend over time.

In this study, the high Ki67 index was another factor significantly associated (p=0.006) with better DFS and showed a trend towards better OS.

Furthermore, individuals with AdipoR1 and AdipoR2 expression showed a trend toward decreased cancer-free survival [ 32 , 33 ].

Total burden score and patient provided with assistance were highly significantly correlated, patient needs help and caregiver stress were moderately significant (Table 3 ).

In contrast, serum eNOS levels showed a decreasing trend with advancing stages of kidney disease.

Considering that the association between ISR and LS BMD gains was attenuated to marginal significance in the multivariate model, whether ISR serves as an independent predictor of treatment response remains unclear.

In the multivariate analysis adjusting for age, these associations were attenuated but remained marginally statistically significant.

Although the vital signs, including oxygenation, remained stable in the prebypass period, perfusionists noticed a decreasing trend in the venous reservoir level early in the CPB operations.

These findings show that there may be significant differences in the mean age of FSGS patients in certain populations.

The mean difference of 2.2 seconds was statistically significant (p<0.001) and comfortably exceeded the TUG MCID threshold, indicating a favorable trend for the integrated protocol over conventional therapy on average.

A highly significant positive correlation was found between anosmia and ageusia durations after COVID-19 recovery (r = 0.6, p = <0.001) (Figure 2 ).

Third, although the power analysis revealed a favorable result, further studies with a larger sample size may reveal different findings because there was a favorable trend toward the ketorolac group in this research, though it was not statistically significant.

Chest CT performed at initial presentation showed only two small pulmonary nodules of indeterminate significance.

These agents offer a clinically significant reduction in depressive symptoms, with an encouraging trend towards early onset of action.

Although psychological well-being also demonstrated an increasing trend, this association did not reach statistical significance.

Interestingly, although psychological well-being showed a positive trend, the association did not reach statistical significance, indicating that emotional adaptation may be influenced by additional factors such as personality traits and social support.

Variables including numeric radiosurgery dose (HR = 1.35; 95% CI 0.99-1.87; p = 0.061) and loss of coordination at clinical presentation (HR = 2.74; 95% CI 0.94-8.02; p = 0.065) showed a trend towards association but did not reach statistical significance.

The p-values observed in our data, such as 1.00 for grade and 1.00 for stage, suggest a possible trend that may become meaningful in a larger cohort study, as Zhang et al.'s study [ 16 ], which showed that TAM density in distinct tumor compartments correlates with patient outcomes.

In the second study, which used the same longitudinal trend analysis approach but used data up to 2022, the authors reported a significant association between HTP use and a decreasing trend of acute coronary syndrome hospitalisations among four subgroups in which HTP use was most prevalent (younger adults, smokers, those residing in Tokyo, and those residing in prefectures with high HTP use).

These effects were statistically significant (i.e., the 95% CIs did not span 1) for dual users and recent quitters/novel product users, and the upper 95% CI of 1 for the cohort of longer‐term quitters/novel product users suggests an effect close to significance.

Table 3 shows the time for first rescue analgesia was significantly increased in group BM (882.94 ±70.22 mins) compared to group B (459 ± 100.53 mins), which was clinically and statistically highly significant.

Cancer type was a highly significant correlate after adjustment for all other covariates.

The patient experienced fairly significant re-pigmentation and reported around 70% improvement on 11 months of treatment with apremilast at 30mg twice daily and two shots of 60mg triamcinolone, first at three months a repeat shot at 4.5 months of treatment [ 16 ].

Furthermore, restricting the database search to the past 10 years (2016-2026) introduces a potential risk of omission, as it may overlook landmark or highly significant foundational studies in this area.